Biotech | May 27, 2022
CorePath partners with Cizzle Bio to develop blood test to detect lung cancer
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
For the third straight year, Lumenis wins an award recognizing outstanding medical companies and technologies
Each member of Fitelo's team of experts gives highly personalized attention and recommendations to their clients ensuring they reach their fitness goals holis
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Subscribe To Our Newsletter & Stay Updated
